# A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors

> **NCT07147348** · PHASE1,PHASE2 · RECRUITING · sponsor: **BioNTech SE** · enrollment: 375 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **BIOLOGICAL:** BNT3212
- **BIOLOGICAL:** Pumitamig

## Key facts

- **NCT ID:** NCT07147348
- **Lead sponsor:** BioNTech SE
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-27
- **Primary completion:** 2027-11
- **Final completion:** 2028-08
- **Target enrollment:** 375 (ESTIMATED)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07147348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07147348, "A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07147348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*